Assessing the Effect of Met DR on Plasma Glucose and PK in Subjects With T2DM
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This study compared the effects of delayed-release metformin (Met DR, EFB0027) administered
once daily in the morning (qAM), administered once daily in the evening (qPM), and
administered twice daily (BID) on circulating glucose concentrations and metformin
pharmacokinetics (PK) in subjects with type 2 diabetes mellitus (T2DM).